Covid and Johnson & Johnson JNJ earnings Q3 2021
[ad_1]
A lab worker holds a vial of Johnson & Johnson’s Janssen coronavirus disease (COVID-19) vaccine.
Johnson & Johnson via Reuters
Johnson & JohnsonIt reported Tuesday’s earnings, which beat Wall Street profit expectations and said that the vaccine company sold $552 million in third-quarter sales of Covid-19.
Here’s how J&J did compared with what Wall Street expected, according to average estimates compiled by Refinitiv:
- Adjusted earnings per share: $2.60 per shares vs. $2.35 anticipated.
- Revenue: $23.34Bn vs. expected $23.72Billion
Shares of J&J jumped more than 1% in premarket trading.
J&J’s report came under a shadow of criticism about how it handled the opioid crisis and the development of a comparatively less-effective Covid vaccine under outgoing CEO Alex Gorsky.
In a press release, Gorsky said the financial results “demonstrate solid performance across Johnson & Johnson, driven by robust above-market results in Pharmaceuticals, ongoing recovery in Medical Devices, and strong growth in Consumer Health.”
This is an ongoing story. Keep checking back for more updates.
[ad_2]